BREAST CANCER

Browse all BREAST CANCER
Updates in Breast Cancer From ASCO 2025

BREAST CANCER

Updates in Breast Cancer From ASCO 2025

Zunairah Shah, MD

5 Key Breast Cancer Clinical Trials Shaping Treatment

BREAST CANCER

5 Key Breast Cancer Clinical Trials Shaping Treatment

Erika Hamilton, MD, FASCO, Sarah Cannon Research Institute

Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management

BREAST CANCER

Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO

Strategic Timing for Multidisciplinary Care in Breast Cancer

BREAST CANCER

Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MD, Matthew Kurian, MD

GI CANCER

Browse all GI CANCER
Preferred Sequencing of Treatment for Neuroendocrine Tumors

GI CANCER

Preferred Sequencing of Treatment for Neuroendocrine Tumors

Deepak Vadehra, DO, Tanios Bekaii-Saab, MD

Five Major Colorectal and GI Cancer Abstracts From 2025 ASCO

GI CANCER

Five Major Colorectal and GI Cancer Abstracts From 2025 ASCO

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Cathy Eng, MD, FACP, FASCO

MATTERHORN Trial: Promising Results and Unanswered Questions

GI CANCER

MATTERHORN Trial: Promising Results and Unanswered Questions

Deepak Vadehra, DO, Supriya Peshin, MD

Diverse Bispecific Strategies Emerging Across GI Cancers

GI CANCER

Diverse Bispecific Strategies Emerging Across GI Cancers

Shruti Patel, MD, Udhayvir Singh Grewal, MD

GU CANCER

Browse all GU CANCER
GU Malignancy Recap from 2025 ASCO

GU CANCER

GU Malignancy Recap from 2025 ASCO

Tian Zhang, MD, MHS

Breakthroughs in Bladder, Prostate, and Kidney Cancer: What Oncologists Need to Know From ASCO 2025

GU CANCER

Breakthroughs in Bladder, Prostate, and Kidney Cancer: What Oncologists Need to Know From ASCO 2025

Saad Atiq, MD

Durvalumab Enters the Perioperative Landscape in Muscle-Invasive Bladder Cancer: Reflections from the NIAGARA Trial and ASCO 2025 Updates

GU CANCER

Durvalumab Enters the Perioperative Landscape in Muscle-Invasive Bladder Cancer: Reflections from the NIAGARA Trial and ASCO 2025 Updates

Charbel Matar, MD

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

GU CANCER

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MD, Michael Serzan, MD

LUNG CANCER

Browse all LUNG CANCER
Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

LUNG CANCER

Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

Kriti Ahuja, MD

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

LUNG CANCER

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

LUNG CANCER

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

ASCO 2025: Key Clinical Trials in Resectable NSCLC

LUNG CANCER

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MD, Mitchell Alexander Parma, MD